SC 13G/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 6)*

Karyopharm Therapeutics Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

48576U106

(CUSIP Number)

Simon Prisk, Esq.

150 East 58th Street, 22nd Floor

New York, NY 10155

(212) 355-3333

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

12/31/20

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 48576U106 13G Page 2 of 12 pages

1.	NAMES OF REPORTING PERSONS Chione Ltd. I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a)    ☐ (b)    ☐
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION CYPRUS

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5.	SOLE VOTING POWER 0
	6.	SHARED VOTING POWER 5,500,000
	7.	SOLE DISPOSITIVE POWER 0
	8.	SHARED DISPOSITIVE POWER 5,500,000

9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,500,000
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)    ☐
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 7.5%
12.	TYPE OF REPORTING PERSON (see instructions) CO

CUSIP No. 48576U106 13G Page 3 of 12 pages

1.	NAMES OF REPORTING PERSONS Marcin Czernik I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a)    ☐ (b)    ☐
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION POLAND

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5.	SOLE VOTING POWER 0
	6.	SHARED VOTING POWER 5,500,000
	7.	SOLE DISPOSITIVE POWER 0
	8.	SHARED DISPOSITIVE POWER 5,500,000

9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,500,000
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)    ☒
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 7.5%
12.	TYPE OF REPORTING PERSON (see instructions) IN, HC

CUSIP No. 48576U106 13G Page 4 of 12 pages

1.	NAMES OF REPORTING PERSONS Andreas Hadjimichael I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a)    ☐ (b)    ☐
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION CYPRUS

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5.	SOLE VOTING POWER 0
	6.	SHARED VOTING POWER 5,500,000
	7.	SOLE DISPOSITIVE POWER 0
	8.	SHARED DISPOSITIVE POWER 5,500,000

9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,500,000
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)    ☒
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 7.5%
12.	TYPE OF REPORTING PERSON (see instructions) IN, HC

CUSIP No. 48576U106 13G Page 5 of 12 pages

1.	NAMES OF REPORTING PERSONS George Hadjimichael I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a)    ☐ (b)    ☐
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION CYPRUS

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5.	SOLE VOTING POWER 0
	6.	SHARED VOTING POWER 5,500,000
	7.	SOLE DISPOSITIVE POWER 0
	8.	SHARED DISPOSITIVE POWER 5,500,000

9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,500,000
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)    ☒
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 7.5%
12.	TYPE OF REPORTING PERSON (see instructions) IN, HC

CUSIP No. 48576U106 13G Page 6 of 12 pages

1.	NAMES OF REPORTING PERSONS Anastasios Nikolaou I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a)    ☐ (b)    ☐
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION CYPRUS

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5.	SOLE VOTING POWER 0
	6.	SHARED VOTING POWER 5,500,000
	7.	SOLE DISPOSITIVE POWER 0
	8.	SHARED DISPOSITIVE POWER 5,500,000

9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,500,000
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)    ☒
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 7.5%
12.	TYPE OF REPORTING PERSON (see instructions) IN, HC

CUSIP No. 48576U106 13G Page 7 of 12 pages

1.	NAMES OF REPORTING PERSONS Wiaczeslaw Smolokowski I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a)    ☐ (b)    ☐
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION POLAND

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5.	SOLE VOTING POWER 0
	6.	SHARED VOTING POWER 5,500,000
	7.	SOLE DISPOSITIVE POWER 0
	8.	SHARED DISPOSITIVE POWER 5,500,000

9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,500,000
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)    ☐
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 7.5%
12.	TYPE OF REPORTING PERSON (see instructions) IN, HC

CUSIP No. 48576U106 13G Page 8 of 12 pages

Item 1.

(a)	Karyopharm Therapeutics Inc.
(b)	Address of Issuer’s Principal Executive Offices 85 Wells Avenue, 2nd Floor Newton, MA 02459

Item 2.

(a)	Name of Person Filing This Statement is filed on behalf of each of the following persons (collectively, the “Reporting Persons”): (i)    Chione Ltd. (“Chione”) (ii)   Marcin Czernik (iii)  Andreas Hadjimichael (iv)  George Hadjimichael (v)   Anastasios Nikolaou (vi) Wiaczeslaw Smolokowski
(b)	Address of the Principal Office or, if none, residence (i)    The principal office of each of the Reporting Persons (other than Mr. Smolokowski) is Simou Menardou 5, Kifisia Court, 2nd Floor, Flat/Office 225, 6015 Larnaca, Cyprus. (ii)   The residence address of Mr. Smolokowski is Chalet Lenotchka, Chemin des Marais 1, Chesieres, Switzerland.
(c)	Citizenship (i)   Chione is a Cyprus corporation. (ii)  Messrs. Andreas and George Hadjimichael and Mr. Anastasios Nikolaou are citizens of the Republic of Cyprus. (iii) Messrs. Czernik and Smolokowski are citizens of the Republic of Poland.
(d)	Title of Class of Securities Common Stock
(e)	CUSIP Number 48576U106

CUSIP No. 048576U106 13G Page 9 of 12 pages

Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

Item 4.  Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a)	Amount beneficially owned: 5,500,000 shares. These shares of Common Stock are owned directly by Chione. Chione’s directors, Marcin Czernik, Andreas Hadjimichael, George Hadjimichael and Anastasios Nikolaou, and its sole stockholder, Wiaczeslaw Smolokowski, may be deemed to share voting and investment power and beneficial ownership of such shares of Common Stock. Each of such directors and stockholder disclaims such voting and investment power and beneficial ownership. The number of shares listed on the cover pages of this Schedule 13G pertaining to Chione’s directors includes the shares of Common Stock owned directly by Chione, but does not include shares of Common Stock owned directly by Plio Ltd., which has the same directors and as to which each of such directors may be deemed to share voting and investment power and beneficial ownership. Each of such directors disclaims such voting and investment power and beneficial ownership.
(b)	Percent of class:  7.5%.  See item 4(a) above.
(c)	Number of shares as to which the person has: Chione
	(i)    Sole power to vote or to direct the vote  0.
	(ii)   Shared power to vote or to direct the vote  5,500,000.
	(iii)  Sole power to dispose or to direct the disposition of  0
	(iv)  Shared power to dispose or to direct the disposition of  5,500,000
	Mr. Czernik

(i)    Sole power to vote or to direct the vote  0.

(ii)   Shared power to vote or to direct the vote  5,500,000.

(iii)  Sole power to dispose or to direct the disposition of  0

(iv)  Shared power to dispose or to direct the disposition of  5,500,000

CUSIP No. 048576U106 13G Page 10 of 12 pages

Mr. Andreas Hadjimichael

(i)    Sole power to vote or to direct the vote  0.

(ii)  Shared power to vote or to direct the vote  5,500,000.

(iii)  Sole power to dispose or to direct the disposition of  0

(iv) Shared power to dispose or to direct the disposition of  5,500,000

Mr. George Hadjimichael

(i)    Sole power to vote or to direct the vote  0.

(ii)  Shared power to vote or to direct the vote  5,500,000.

(iii)  Sole power to dispose or to direct the disposition of  0

(iv) Shared power to dispose or to direct the disposition of  5,500,000

Mr. Nikolaou

(i)    Sole power to vote or to direct the vote  0.

(ii)  Shared power to vote or to direct the vote  5,500,000.

(iii)  Sole power to dispose or to direct the disposition of  0

(iv) Shared power to dispose or to direct the disposition of  5,500,000

CUSIP No. 048576U106 13G Page 11 of 12 pages

Mr. Wiaczeslaw Smolokowski

(i)   Sole power to vote or to direct the vote 0.

(ii)  Shared power to vote or to direct the vote 5,500,000.

(iii) Sole power to dispose or to direct the disposition of 0

(iv) Shared power to dispose or to direct the disposition of 5,500,000

See item 4(a) above.

Item 5.  Ownership of Five Percent or Less of a Class.

Not applicable.

Item 6.  Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

Not applicable.

Item 8.  Identification and Classification of Members of the Group.

Not applicable.

Item 9.  Notice of Dissolution of Group.

Not applicable.

Item 10.  Certification.

Not applicable.

CUSIP No. 048576U106 13G Page 12 of 12 pages

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 16, 2021

Date

Chione Limited, by /s/ Simon Prisk,
	as attorney-in-fact
Marcin Czernik, by /s/ Simon Prisk,
	as attorney-in-fact
Andreas Hadjimichael, by /s/ Simon Prisk,
	as attorney-in-fact
George Hadjimichael, by /s/ Simon Prisk,
	as attorney-in-fact
Anastasios Nikolaou, by /s/ Simon Prisk,
	as attorney-in-fact
Wiaczeslaw Smolokowski, by /s/ Simon Prisk,
	as attorney-in-fact

Exhibit Index

Exhibit 24.1	-	Power of Attorney, dated as of February 12, 2021, made by Marcin Czernik and Chione Limited in favor of Simon Prisk
Exhibit 24.2	-	Power of Attorney, dated as of February 12, 2021, made by Andreas Hadjimichael and Chione Limited in favor of Simon Prisk
Exhibit 24.3	-	Power of Attorney, dated February 12, 2021, made by George Hadjimichael and Chione Limited in favor of Simon Prisk
Exhibit 24.4	-	Power of Attorney, dated February 12, 2021, made by Wiaczeslaw Smolokowski in favor of Simon Prisk
Exhibit 24.5	-	Power of Attorney, dated February 12, 2021, made by Anastasios Nikolaou and Chione Limited in favor of Simon Prisk
Exhibit 99.1	-	Joint Filing Agreement, dated February 16, 2021, among the Reporting Persons

EX-24.1

Exhibit 24.1

LIMITED POWER OF ATTORNEY

The undersigned, Marcin Czernik, hereby appoints Simon Prisk as his attorney-in-fact (i) for and on behalf of the undersigned, including, without limitation, in my current or future capacity as a director and, if applicable, as an officer of Chione Limited (the “Company”), and (ii) for and on behalf of the Company, in each case, in respect of (A) any current or future direct or indirect beneficial ownership of, or pecuniary interest in (whether or not such beneficial ownership or pecuniary interest is disclaimed), securities of Karyopharm Therapeutics Inc., including any successor entity (“KTI”), and (B) any other status or transaction of or involving the undersigned and/or the Company requiring any filing or report pursuant to the Securities Exchange Act of 1934 and the rules and regulations thereunder or applicable thereto (the “Exchange Act”) in respect of such securities, including, without limitation, pursuant to Section 13 or 16 of the Exchange Act. Such appointment as attorney-in-fact shall include, without limitation, the power and authority:

1. to execute and file a Form ID on behalf of the undersigned and otherwise to secure any codes required in order for the undersigned to be able to file with the U.S. Securities and Exchange Commission’s Edgar system;

2. to execute and file any Form 3, Form 4, or Form 5, Schedule 13G or 13D, any amendments to any such Form or Schedule, and any filing agreements related to securities of KTI on behalf of the undersigned and/or the Company;

3. to seek and obtain information on behalf of, and as the representative of the undersigned and/or the Company, from any and all persons, including, without limitation, representatives of the Company and KTI, in connection with the foregoing; and

4. to do and perform any and all acts and things, including, without limitation, to execute, submit and file such agreements, instruments, forms and other documents, to incur such expenses, as may be necessary or desirable, in the sole discretion of such attorney-in-fact, in connection with the foregoing, it being understood that the documents executed by such attorney-in-fact pursuant to this Limited Power of Attorney shall be in such form and shall contain such information as such attorney-in-fact may approve in such attorney-in-fact’s sole discretion.

The undersigned acknowledges that said attorney-in-fact is not assuming any of my responsibilities to comply with the Exchange Act.

Said attorney-in-fact may (i) act in reliance upon the signature below; and (ii) assume that any person, whether as an individual or as a person who has been designated by the Company or KTI or any other person to give any written instructions, notice or receipt, or make any statements in connection with the foregoing matters (or any of them) has been duly authorized to do so. 

Said attorney-in-fact shall have no duty to make inquiry as to the genuineness, accuracy or validity of any statements or instructions or any signatures or instructions.   

This Limited Power of Attorney will remain in effect until February 12, 2022 or until such earlier time as a written revocation of this Limited Power of Attorney is delivered to said attorney-in-fact at the then current address of the Ruchelman Law Firm.

The undersigned is signing this Limited Power of Attorney as of February 12, 2021.

/s/ Marcin Czernik

Marcin Czernik, individually, including in his capacity as an officer and/or director of the Company (as applicable), and on behalf of the Company

EX-24.2

Exhibit 24.2

LIMITED POWER OF ATTORNEY

The undersigned, Andreas Hadjimichael, hereby appoints Simon Prisk as his attorney-in-fact (i) for and on behalf of the undersigned, including, without limitation, in my current or future capacity as a director and, if applicable, as an officer of Chione Limited (the “Company”), and (ii) for and on behalf of the Company, in each case, in respect of (A) any current or future direct or indirect beneficial ownership of, or pecuniary interest in (whether or not such beneficial ownership or pecuniary interest is disclaimed), securities of Karyopharm Therapeutics Inc., including any successor entity (“KTI”), and (B) any other status or transaction of or involving the undersigned and/or the Company requiring any filing or report pursuant to the Securities Exchange Act of 1934 and the rules and regulations thereunder or applicable thereto (the “Exchange Act”) in respect of such securities, including, without limitation, pursuant to Section 13 or 16 of the Exchange Act. Such appointment as attorney-in-fact shall include, without limitation, the power and authority:

1. to execute and file a Form ID on behalf of the undersigned and otherwise to secure any codes required in order for the undersigned to be able to file with the U.S. Securities and Exchange Commission’s Edgar system;

2. to execute and file any Form 3, Form 4, or Form 5, Schedule 13G or 13D, any amendments to any such Form or Schedule, and any filing agreements related to securities of KTI on behalf of the undersigned and/or the Company;

3. to seek and obtain information on behalf of, and as the representative of the undersigned and/or the Company, from any and all persons, including, without limitation, representatives of the Company and KTI, in connection with the foregoing; and

4. to do and perform any and all acts and things, including, without limitation, to execute, submit and file such agreements, instruments, forms and other documents, to incur such expenses, as may be necessary or desirable, in the sole discretion of such attorney-in-fact, in connection with the foregoing, it being understood that the documents executed by such attorney-in-fact pursuant to this Limited Power of Attorney shall be in such form and shall contain such information as such attorney-in-fact may approve in such attorney-in-fact’s sole discretion.

The undersigned acknowledges that said attorney-in-fact is not assuming any of my responsibilities to comply with the Exchange Act.

Said attorney-in-fact may (i) act in reliance upon the signature below; and (ii) assume that any person, whether as an individual or as a person who has been designated by the Company or KTI or any other person to give any written instructions, notice or receipt, or make any statements in connection with the foregoing matters (or any of them) has been duly authorized to do so. 

Said attorney-in-fact shall have no duty to make inquiry as to the genuineness, accuracy or validity of any statements or instructions or any signatures or instructions.   

This Limited Power of Attorney will remain in effect until February 12, 2022 or until such earlier time as a written revocation of this Limited Power of Attorney is delivered to said attorney-in-fact at the then current address of the Ruchelman Law Firm.

The undersigned is signing this Limited Power of Attorney as of February 12, 2021.

/s/ Andreas Hadjimichael

Andreas Hadjimichael, individually, including in his capacity as an officer and/or director of the Company (as applicable), and on behalf of the Company

EX-24.3

Exhibit 24.3

LIMITED POWER OF ATTORNEY

The undersigned, George Hadjimichael, hereby appoints Simon Prisk as his attorney-in-fact (i) for and on behalf of the undersigned, including, without limitation, in my current or future capacity as a director and, if applicable, as an officer of Chione Limited (the “Company”), and (ii) for and on behalf of the Company, in each case, in respect of (A) any current or future direct or indirect beneficial ownership of, or pecuniary interest in (whether or not such beneficial ownership or pecuniary interest is disclaimed), securities of Karyopharm Therapeutics Inc., including any successor entity (“KTI”), and (B) any other status or transaction of or involving the undersigned and/or the Company requiring any filing or report pursuant to the Securities Exchange Act of 1934 and the rules and regulations thereunder or applicable thereto (the “Exchange Act”) in respect of such securities, including, without limitation, pursuant to Section 13 or 16 of the Exchange Act. Such appointment as attorney-in-fact shall include, without limitation, the power and authority:

1. to execute and file a Form ID on behalf of the undersigned and otherwise to secure any codes required in order for the undersigned to be able to file with the U.S. Securities and Exchange Commission’s Edgar system;

2. to execute and file any Form 3, Form 4, or Form 5, Schedule 13G or 13D, any amendments to any such Form or Schedule, and any filing agreements related to securities of KTI on behalf of the undersigned and/or the Company;

3. to seek and obtain information on behalf of, and as the representative of the undersigned and/or the Company, from any and all persons, including, without limitation, representatives of the Company and KTI, in connection with the foregoing; and

4. to do and perform any and all acts and things, including, without limitation, to execute, submit and file such agreements, instruments, forms and other documents, to incur such expenses, as may be necessary or desirable, in the sole discretion of such attorney-in-fact, in connection with the foregoing, it being understood that the documents executed by such attorney-in-fact pursuant to this Limited Power of Attorney shall be in such form and shall contain such information as such attorney-in-fact may approve in such attorney-in-fact’s sole discretion.

The undersigned acknowledges that said attorney-in-fact is not assuming any of my responsibilities to comply with the Exchange Act.

Said attorney-in-fact may (i) act in reliance upon the signature below; and (ii) assume that any person, whether as an individual or as a person who has been designated by the Company or KTI or any other person to give any written instructions, notice or receipt, or make any statements in connection with the foregoing matters (or any of them) has been duly authorized to do so. 

Said attorney-in-fact shall have no duty to make inquiry as to the genuineness, accuracy or validity of any statements or instructions or any signatures or instructions. 

This Limited Power of Attorney will remain in effect until February 12, 2022 or until such earlier time as a written revocation of this Limited Power of Attorney is delivered to said attorney-in-fact at the then current address of the Ruchelman Law Firm.

The undersigned is signing this Limited Power of Attorney as of February 12, 2021.

/s/ George Hadjimichael

George Hadjimichael, individually, including in his capacity as an officer and/or director of the Company (as applicable), and on behalf of the Company

EX-24.4

Exhibit 24.4

LIMITED POWER OF ATTORNEY

The undersigned, Wiaczeslaw Smolokowski, hereby appoints Simon Prisk as his attorney-in-fact for and on behalf of the undersigned, in respect of (A) any current or future direct or indirect beneficial ownership of, or pecuniary interest in (whether or not such beneficial ownership or pecuniary interest is disclaimed), securities of Karyopharm Therapeutics Inc., including any successor entity (“KTI”), and (B) any other status, including, if applicable, as an officer or director of Chione Limited (the “Company”), or transaction of or involving the undersigned and/or the Company requiring any filing or report pursuant to the Securities Exchange Act of 1934 and the rules and regulations thereunder or applicable thereto (the “Exchange Act”) in respect of such securities, including, without limitation, pursuant to Section 13 or 16 of the Exchange Act. Such appointment as attorney-in-fact shall include, without limitation, the power and authority:

1. to execute and file a Form ID on behalf of the undersigned and otherwise to secure any codes required in order for the undersigned to be able to file with the U.S. Securities and Exchange Commission’s Edgar system;

2. to execute and file any Form 3, Form 4, or Form 5, Schedule 13G or 13D, any amendments to any such Form or Schedule, and any filing agreements related to securities of KTI on behalf of the undersigned and/or the Company;

3. to seek and obtain information on behalf of, and as the representative of the undersigned and/or the Company, from any and all persons, including, without limitation, representatives of the Company and KTI, in connection with the foregoing; and

4. to do and perform any and all acts and things, including, without limitation, to execute, submit and file such agreements, instruments, forms and other documents, to incur such expenses, as may be necessary or desirable, in the sole discretion of such attorney-in-fact, in connection with the foregoing, it being understood that the documents executed by such attorney-in-fact pursuant to this Limited Power of Attorney shall be in such form and shall contain such information as such attorney-in-fact may approve in such attorney-in-fact’s sole discretion.

The undersigned acknowledges that said attorney-in-fact is not assuming any of my responsibilities to comply with the Exchange Act.

Said attorney-in-fact may (i) act in reliance upon the signature below; and (ii) assume that any person, whether as an individual or as a person who has been designated by the Company or KTI or any other person to give any written instructions, notice or receipt, or make any statements in connection with the foregoing matters (or any of them) has been duly authorized to do so. 

Said attorney-in-fact shall have no duty to make inquiry as to the genuineness, accuracy or validity of any statements or instructions or any signatures or instructions.   

This Limited Power of Attorney will remain in effect until February 12, 2022 or until such earlier time as a written revocation of this Limited Power of Attorney is delivered to said attorney-in-fact at the then current address of the Ruchelman Law Firm.

The undersigned is signing this Limited Power of Attorney as of February 12, 2021.

/s/ Wiaczeslaw Smolokowski

Wiaczeslaw Smolokowski

EX-24.5

Exhibit 24.5

LIMITED POWER OF ATTORNEY

The undersigned, Anastasios Nikolaou, hereby appoints Simon Prisk as his attorney-in-fact (i) for and on behalf of the undersigned, including, without limitation, in my current or future capacity as a director and, if applicable, as an officer of Chione Limited (the “Company”), and (ii) for and on behalf of the Company, in each case, in respect of (A) any current or future direct or indirect beneficial ownership of, or pecuniary interest in (whether or not such beneficial ownership or pecuniary interest is disclaimed), securities of Karyopharm Therapeutics Inc., including any successor entity (“KTI”), and (B) any other status or transaction of or involving the undersigned and/or the Company requiring any filing or report pursuant to the Securities Exchange Act of 1934 and the rules and regulations thereunder or applicable thereto (the “Exchange Act”) in respect of such securities, including, without limitation, pursuant to Section 13 or 16 of the Exchange Act. Such appointment as attorney-in-fact shall include, without limitation, the power and authority:

1. to execute and file a Form ID on behalf of the undersigned and otherwise to secure any codes required in order for the undersigned to be able to file with the U.S. Securities and Exchange Commission’s Edgar system;

2. to execute and file any Form 3, Form 4, or Form 5, Schedule 13G or 13D, any amendments to any such Form or Schedule, and any filing agreements related to securities of KTI on behalf of the undersigned and/or the Company;

3. to seek and obtain information on behalf of, and as the representative of the undersigned and/or the Company, from any and all persons, including, without limitation, representatives of the Company and KTI, in connection with the foregoing; and

4. to do and perform any and all acts and things, including, without limitation, to execute, submit and file such agreements, instruments, forms and other documents, to incur such expenses, as may be necessary or desirable, in the sole discretion of such attorney-in-fact, in connection with the foregoing, it being understood that the documents executed by such attorney-in-fact pursuant to this Limited Power of Attorney shall be in such form and shall contain such information as such attorney-in-fact may approve in such attorney-in-fact’s sole discretion.

The undersigned acknowledges that said attorney-in-fact is not assuming any of my responsibilities to comply with the Exchange Act.

Said attorney-in-fact may (i) act in reliance upon the signature below; and (ii) assume that any person, whether as an individual or as a person who has been designated by the Company or KTI or any other person to give any written instructions, notice or receipt, or make any statements in connection with the foregoing matters (or any of them) has been duly authorized to do so. 

Said attorney-in-fact shall have no duty to make inquiry as to the genuineness, accuracy or validity of any statements or instructions or any signatures or instructions.   

This Limited Power of Attorney will remain in effect until February 12, 2022 or until such earlier time as a written revocation of this Limited Power of Attorney is delivered to said attorney-in-fact at the then current address of the Ruchelman Law Firm.

The undersigned is signing this Limited Power of Attorney as of February 12, 2021.

/s/ Anastasios Nikolaou

Anastasios Nikolaou, individually, including in his capacity as an officer and/or director of the Company (as applicable), and on behalf of the Company

EX-99.1

EXHIBIT 99.1

JOINT FILING AGREEMENT

The undersigned hereby agree that Amendment No. 6 to the Schedule 13G, dated as of February 16, 2021, with respect to the Common Stock of Karyopharm Therapeutics Inc. is, and any amendments thereto, any Schedule 13D with respect to such Common Stock, and any amendments thereto, signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(f) under the Securities Exchange Act of 1934.

Dated: February 16, 2021	Chione Ltd., by /s/ Simon Prisk,
		as attorney-in-fact
	Marcin Czernik, by /s/ Simon Prisk,
		as attorney-in-fact
	Andreas Hadjimichael, by /s/ Simon Prisk,
		as attorney-in-fact
	George Hadjimichael, by /s/ Simon Prisk,
		as attorney-in- fact
	Anastasios Nikolaou, by /s/ Simon Prisk,
		as attorney-in- fact
	Wiaczeslaw Smolokowski, by /s/ Simon Prisk,
		as attorney-in-fact